Table of Contents

1 Report Business Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Metabolic Disease Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
  • 1.2.2 Glycogen Metabolism Disease Drug
  • 1.2.3 Lipid Metabolism Disease Drug
  • 1.2.4 Amino Acid Metabolism Drug
  • 1.2.5 Other
• 1.3 Market by Application
  • 1.3.1 Global Metabolic Disease Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Retail Pharmacy
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Metabolic Disease Drugs Market Perspective (2017-2028)
• 2.2 Metabolic Disease Drugs Growth Trends by Region
  • 2.2.1 Metabolic Disease Drugs Market Size by Region: 2017 VS 2021 VS 2028
  • 2.2.2 Metabolic Disease Drugs Historic Market Size by Region (2017-2022)
  • 2.2.3 Metabolic Disease Drugs Forecasted Market Size by Region (2023-2028)
• 2.3 Metabolic Disease Drugs Market Dynamics
  • 2.3.1 Metabolic Disease Drugs Industry Trends
  • 2.3.2 Metabolic Disease Drugs Market Drivers
  • 2.3.3 Metabolic Disease Drugs Market Challenges
  • 2.3.4 Metabolic Disease Drugs Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Metabolic Disease Drugs Players by Revenue
  • 3.1.1 Global Top Metabolic Disease Drugs Players by Revenue (2017-2022)
  • 3.1.2 Global Metabolic Disease Drugs Revenue Market Share by Players (2017-2022)
• 3.2 Global Metabolic Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Players Covered: Ranking by Metabolic Disease Drugs Revenue
• 3.4 Global Metabolic Disease Drugs Market Concentration Ratio
  • 3.4.1 Global Metabolic Disease Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disease Drugs Revenue in 2021
• 3.5 Metabolic Disease Drugs Key Players Head office and Area Served
• 3.6 Key Players Metabolic Disease Drugs Product Solution and Service
• 3.7 Date of Enter into Metabolic Disease Drugs Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Metabolic Disease Drugs Breakdown Data by Type

• 4.1 Global Metabolic Disease Drugs Historic Market Size by Type (2017-2022)
• 4.2 Global Metabolic Disease Drugs Forecasted Market Size by Type (2023-2028)

5 Metabolic Disease Drugs Breakdown Data by Application

• 5.1 Global Metabolic Disease Drugs Historic Market Size by Application (2017-2022)
• 5.2 Global Metabolic Disease Drugs Forecasted Market Size by Application (2023-2028)

6 North America

• 6.1 North America Metabolic Disease Drugs Market Size (2017-2028)
• 6.2 North America Metabolic Disease Drugs Market Size by Type
  • 6.2.1 North America Metabolic Disease Drugs Market Size by Type (2017-2022)
  • 6.2.2 North America Metabolic Disease Drugs Market Size by Type (2023-2028)
  • 6.2.3 North America Metabolic Disease Drugs Market Share by Type (2017-2028)
• 6.3 North America Metabolic Disease Drugs Market Size by Application
  • 6.3.1 North America Metabolic Disease Drugs Market Size by Application (2017-2022)
  • 6.3.2 North America Metabolic Disease Drugs Market Size by Application (2023-2028)
  • 6.3.3 North America Metabolic Disease Drugs Market Share by Application (2017-2028)
• 6.4 North America Metabolic Disease Drugs Market Size by Country
  • 6.4.1 North America Metabolic Disease Drugs Market Size by Country (2017-2022)
  • 6.4.2 North America Metabolic Disease Drugs Market Size by Country (2023-2028)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Metabolic Disease Drugs Market Size (2017-2028)
• 7.2 Europe Metabolic Disease Drugs Market Size by Type
  • 7.2.1 Europe Metabolic Disease Drugs Market Size by Type (2017-2022)
  • 7.2.2 Europe Metabolic Disease Drugs Market Size by Type (2023-2028)
  • 7.2.3 Europe Metabolic Disease Drugs Market Share by Type (2017-2028)
• 7.3 Europe Metabolic Disease Drugs Market Size by Application
  • 7.3.1 Europe Metabolic Disease Drugs Market Size by Application (2017-2022)
  • 7.3.2 Europe Metabolic Disease Drugs Market Size by Application (2023-2028)
  • 7.3.3 Europe Metabolic Disease Drugs Market Share by Application (2017-2028)
• 7.4 Europe Metabolic Disease Drugs Market Size by Country
  • 7.4.1 Europe Metabolic Disease Drugs Market Size by Country (2017-2022)
  • 7.4.2 Europe Metabolic Disease Drugs Market Size by Country (2023-2028)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic Countries

8 Asia-Pacific

• 8.1 Asia-Pacific Metabolic Disease Drugs Market Size (2017-2028)
• 8.2 Asia-Pacific Metabolic Disease Drugs Market Size by Type
  • 8.2.1 Asia-Pacific Metabolic Disease Drugs Market Size by Type (2017-2022)
  • 8.2.2 Asia-Pacific Metabolic Disease Drugs Market Size by Type (2023-2028)
  • 8.2.3 Asia-Pacific Metabolic Disease Drugs Market Share by Type (2017-2028)
• 8.3 Asia-Pacific Metabolic Disease Drugs Market Size by Application
  • 8.3.1 Asia-Pacific Metabolic Disease Drugs Market Size by Application (2017-2022)
  • 8.3.2 Asia-Pacific Metabolic Disease Drugs Market Size by Application (2023-2028)
  • 8.3.3 Asia-Pacific Metabolic Disease Drugs Market Share by Application (2017-2028)
• 8.4 Asia-Pacific Metabolic Disease Drugs Market Size by Region
  • 8.4.1 Asia-Pacific Metabolic Disease Drugs Market Size by Region (2017-2022)
  • 8.4.2 Asia-Pacific Metabolic Disease Drugs Market Size by Region (2023-2028)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Metabolic Disease Drugs Market Size (2017-2028)
• 9.2 Latin America Metabolic Disease Drugs Market Size by Type
  • 9.2.1 Latin America Metabolic Disease Drugs Market Size by Type (2017-2022)
  • 9.2.2 Latin America Metabolic Disease Drugs Market Size by Type (2023-2028)
  • 9.2.3 Latin America Metabolic Disease Drugs Market Share by Type (2017-2028)
• 9.3 Latin America Metabolic Disease Drugs Market Size by Application
  • 9.3.1 Latin America Metabolic Disease Drugs Market Size by Application (2017-2022)
  • 9.3.2 Latin America Metabolic Disease Drugs Market Size by Application (2023-2028)
  • 9.3.3 Latin America Metabolic Disease Drugs Market Share by Application (2017-2028)
• 9.4 Latin America Metabolic Disease Drugs Market Size by Country
  • 9.4.1 Latin America Metabolic Disease Drugs Market Size by Country (2017-2022)
  • 9.4.2 Latin America Metabolic Disease Drugs Market Size by Country (2023-2028)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Metabolic Disease Drugs Market Size (2017-2028)
• 10.2 Middle East & Africa Metabolic Disease Drugs Market Size by Type
  • 10.2.1 Middle East & Africa Metabolic Disease Drugs Market Size by Type (2017-2022)
  • 10.2.2 Middle East & Africa Metabolic Disease Drugs Market Size by Type (2023-2028)
  • 10.2.3 Middle East & Africa Metabolic Disease Drugs Market Share by Type (2017-2028)
• 10.3 Middle East & Africa Metabolic Disease Drugs Market Size by Application
  • 10.3.1 Middle East & Africa Metabolic Disease Drugs Market Size by Application (2017-2022)
  • 10.3.2 Middle East & Africa Metabolic Disease Drugs Market Size by Application (2023-2028)
  • 10.3.3 Middle East & Africa Metabolic Disease Drugs Market Share by Application (2017-2028)
• 10.4 Middle East & Africa Metabolic Disease Drugs Market Size by Country
  • 10.4.1 Middle East & Africa Metabolic Disease Drugs Market Size by Country (2017-2022)
  • 10.4.2 Middle East & Africa Metabolic Disease Drugs Market Size by Country (2023-2028)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Merck
  • 11.1.1 Merck Company Details
  • 11.1.2 Merck Business Overview
  • 11.1.3 Merck Metabolic Disease Drugs Introduction
  • 11.1.4 Merck Revenue in Metabolic Disease Drugs Business (2017-2022)
  • 11.1.5 Merck Recent Developments
• 11.2 Novartis
  • 11.2.1 Novartis Company Details
  • 11.2.2 Novartis Business Overview
  • 11.2.3 Novartis Metabolic Disease Drugs Introduction
  • 11.2.4 Novartis Revenue in Metabolic Disease Drugs Business (2017-2022)
  • 11.2.5 Novartis Recent Developments
• 11.3 Takeda Pharmaceutical
  • 11.3.1 Takeda Pharmaceutical Company Details
  • 11.3.2 Takeda Pharmaceutical Business Overview
  • 11.3.3 Takeda Pharmaceutical Metabolic Disease Drugs Introduction
  • 11.3.4 Takeda Pharmaceutical Revenue in Metabolic Disease Drugs Business (2017-2022)
  • 11.3.5 Takeda Pharmaceutical Recent Developments
• 11.4 Astra Zeneca
  • 11.4.1 Astra Zeneca Company Details
  • 11.4.2 Astra Zeneca Business Overview
  • 11.4.3 Astra Zeneca Metabolic Disease Drugs Introduction
  • 11.4.4 Astra Zeneca Revenue in Metabolic Disease Drugs Business (2017-2022)
  • 11.4.5 Astra Zeneca Recent Developments
• 11.5 Beohrigher Ingelheim
  • 11.5.1 Beohrigher Ingelheim Company Details
  • 11.5.2 Beohrigher Ingelheim Business Overview
  • 11.5.3 Beohrigher Ingelheim Metabolic Disease Drugs Introduction
  • 11.5.4 Beohrigher Ingelheim Revenue in Metabolic Disease Drugs Business (2017-2022)
  • 11.5.5 Beohrigher Ingelheim Recent Developments
• 11.6 KOWA
  • 11.6.1 KOWA Company Details
  • 11.6.2 KOWA Business Overview
  • 11.6.3 KOWA Metabolic Disease Drugs Introduction
  • 11.6.4 KOWA Revenue in Metabolic Disease Drugs Business (2017-2022)
  • 11.6.5 KOWA Recent Developments
• 11.7 Kythera
  • 11.7.1 Kythera Company Details
  • 11.7.2 Kythera Business Overview
  • 11.7.3 Kythera Metabolic Disease Drugs Introduction
  • 11.7.4 Kythera Revenue in Metabolic Disease Drugs Business (2017-2022)
  • 11.7.5 Kythera Recent Developments
• 11.8 Fuji yakuhin
  • 11.8.1 Fuji yakuhin Company Details
  • 11.8.2 Fuji yakuhin Business Overview
  • 11.8.3 Fuji yakuhin Metabolic Disease Drugs Introduction
  • 11.8.4 Fuji yakuhin Revenue in Metabolic Disease Drugs Business (2017-2022)
  • 11.8.5 Fuji yakuhin Recent Developments
• 11.9 LG Life Science
  • 11.9.1 LG Life Science Company Details
  • 11.9.2 LG Life Science Business Overview
  • 11.9.3 LG Life Science Metabolic Disease Drugs Introduction
  • 11.9.4 LG Life Science Revenue in Metabolic Disease Drugs Business (2017-2022)
  • 11.9.5 LG Life Science Recent Developments
• 11.10 Metsubishi Tanabe Pharma
  • 11.10.1 Metsubishi Tanabe Pharma Company Details
  • 11.10.2 Metsubishi Tanabe Pharma Business Overview
  • 11.10.3 Metsubishi Tanabe Pharma Metabolic Disease Drugs Introduction
  • 11.10.4 Metsubishi Tanabe Pharma Revenue in Metabolic Disease Drugs Business (2017-2022)
  • 11.10.5 Metsubishi Tanabe Pharma Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Author Details

Summary:

Market Analysis and Insights: Global Metabolic Disease Drugs Market
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
The global Metabolic Disease Drugs market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Glycogen Metabolism Disease Drug accounting for % of the Metabolic Disease Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.
China Metabolic Disease Drugs market size is valued at US$ million in 2021, while the North America and Europe Metabolic Disease Drugs are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Metabolic Disease Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Metabolic Disease Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Metabolic Disease Drugs market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Metabolic Disease Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Metabolic Disease Drugs market.
Impact of Covid-19 Outbreak
This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
Segmental Analysis
The report has been segmented into product and application segments. The researchers have documented all the products present today in the Metabolic Disease Drugs market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.
Metabolic Disease Drugs Breakdown Data by Type
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Metabolic Disease Drugs Breakdown Data by Application
Hospital Pharmacy
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape
This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Beohrigher Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Frequently Asked Questions
What factors will challenge the Metabolic Disease Drugs market growth?
Which end-use segment will expand at the fastest CAGR in the Metabolic Disease Drugs market?
Which are the emerging players in the Metabolic Disease Drugs market?
How concentrated is the Metabolic Disease Drugs market?
Which factors are positively contributing to the Metabolic Disease Drugs market growth?
Which are the novel product innovations in the Metabolic Disease Drugs market?
Which product segment will emerge as the most lucrative in the Metabolic Disease Drugs market?
Which factors are increasing the competition in the Metabolic Disease Drugs market?
Which are the strategic measures taken by the Metabolic Disease Drugs industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Metabolic Disease Drugs market in the coming years?